Production & Manufacturing
Production & Manufacturing
AstraZeneca enters commercialisation agreement with Aspen for  anaesthetics portfolio
AstraZeneca announced that it has completed the commercialisation agreement with Aspen Global Incorporated (AGI), part of the Aspen Group, for rights to its global anaesthetics portfolio outside the US. The agreement covers seven established medicines -...
Production & Manufacturing
TaiGen Biotechnology Out-Licenses Taigexyn® (Nemonoxacin) to Productos CientÃficos for the Latin American Market
TaiGen Biotechnology Company, Limited announced that they have signed an exclusive licensing agreement with Productos CientÃficos S.A. de C.V. ("PC"), a leading Mexican pharmaceutical company, to develop and commercialize Taigexyn® (nemonoxacin) in Latin America. Taigexyn® is...
Production & Manufacturing
Janssen Submits Application to U.S. FDA to Expand Indication for Daratumumab Â
Janssen Biotech, Inc. announced a supplemental Biologics License Application (sBLA) for daratumumab (DARZALEX®) has been submitted to the U.S. FDA . The application seeks to expand the current indication, using daratumumab in combination with lenalidomide (an...
Production & Manufacturing
Agilent Chooses Colorado for New Pharma Manufacturing Facility
Agilent Technologies reports that it acquired 20 acres in Weld County in northern Colorado, on which it plans to build a pharmaceutical manufacturing facility. “The products manufactured at this site will be used by our customers...
Production & Manufacturing
Alexion issued new FDA Form 483 for Rhode Island plant
The FDA has again raised issues at an Alexion plant that three years ago was issued a warning letter. The facility is where Alexion manufactures what has been deemed the world’s most expensive drug, Soliris. Alexion...
Production & Manufacturing
Pfizer suspends work at Hospira India plant as FDA turns up heat
Pfizer is being schooled in the challenges of sterile drug manufacturing that come with its $15 billion buyout of Hospira. The New York drug giant has temporarily suspended production at a plant in India that the FDA cited three...
Production & Manufacturing
Aurobindo breaks ground on New Jersey facility
Aurobindo is starting to build on its pledge to expand operations in New Jersey, literally. The Indian drugmaker this week broke ground on the 567,000-square-foot facility that is slated to include a manufacturing and distribution center and warehouse, according...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read